CN102573895A - 减少抗-抗体反应的方法、组合物和试剂盒 - Google Patents

减少抗-抗体反应的方法、组合物和试剂盒 Download PDF

Info

Publication number
CN102573895A
CN102573895A CN2010800468261A CN201080046826A CN102573895A CN 102573895 A CN102573895 A CN 102573895A CN 2010800468261 A CN2010800468261 A CN 2010800468261A CN 201080046826 A CN201080046826 A CN 201080046826A CN 102573895 A CN102573895 A CN 102573895A
Authority
CN
China
Prior art keywords
allotype
monoclonal antibody
phenotype
subject
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800468261A
Other languages
English (en)
Chinese (zh)
Inventor
J·西马德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XBIOTECH Inc
Original Assignee
XBIOTECH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XBIOTECH Inc filed Critical XBIOTECH Inc
Publication of CN102573895A publication Critical patent/CN102573895A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800468261A 2009-09-24 2010-09-23 减少抗-抗体反应的方法、组合物和试剂盒 Pending CN102573895A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24530509P 2009-09-24 2009-09-24
US61/245,305 2009-09-24
PCT/US2010/049924 WO2011038069A1 (en) 2009-09-24 2010-09-23 Methods, compositions, and kits for reducing anti-antibody responses

Publications (1)

Publication Number Publication Date
CN102573895A true CN102573895A (zh) 2012-07-11

Family

ID=43756813

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800468261A Pending CN102573895A (zh) 2009-09-24 2010-09-23 减少抗-抗体反应的方法、组合物和试剂盒

Country Status (8)

Country Link
US (6) US20110071054A1 (https=)
EP (1) EP2480252A4 (https=)
JP (1) JP2013505938A (https=)
KR (1) KR20120093229A (https=)
CN (1) CN102573895A (https=)
AU (1) AU2010298264B2 (https=)
CA (1) CA2775291A1 (https=)
WO (1) WO2011038069A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) * 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP2013505938A (ja) * 2009-09-24 2013-02-21 エックスバイオテク，インコーポレイテッド 抗抗体応答を軽減する方法、組成物およびキット
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
JP2014523884A (ja) * 2011-06-24 2014-09-18 セントローズ， エルエルシー 細胞外標的化薬物複合体
US20130089496A1 (en) * 2011-10-07 2013-04-11 Musc Foundation For Research Development Tumor targeted antibodies and method for using the same
US10282875B2 (en) 2015-12-11 2019-05-07 International Business Machines Corporation Graph-based analysis for bio-signal event sensing
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792838A (en) * 1991-10-28 1998-08-11 Glaxo Wellcome Inc. Method for stabilizing immunoglobulin compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
AU5152293A (en) * 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5856095A (en) * 1995-08-14 1999-01-05 St. Jude Children's Research Hospital Identification of two novel mutant alleles of human thiopurine S-methyltransferase, and diagnostic uses thereof
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
GB9925490D0 (en) * 1999-10-28 1999-12-29 Univ Cambridge Tech Binding molecules and treatment and screening methods
US20020127625A1 (en) * 2000-03-31 2002-09-12 Forskarpatent Is Syd Ab Methods of diagnosing immune related diseases
EP2288733A4 (en) * 2008-03-18 2012-03-21 Merck Sharp & Dohme PROTEIN CHANGE TEST WITH HIGH THROUGHPUT
JP2013505938A (ja) * 2009-09-24 2013-02-21 エックスバイオテク，インコーポレイテッド 抗抗体応答を軽減する方法、組成物およびキット

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792838A (en) * 1991-10-28 1998-08-11 Glaxo Wellcome Inc. Method for stabilizing immunoglobulin compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEUZELIN ET AL: "lgG1 heavy chain-coding gene polyomorphism and development of antibodies-to-inflicimab", 《PHARMACOGENET GENOMICS 》, vol. 19, no. 5, 30 May 2009 (2009-05-30), pages 383 - 7 *
GORMAN SD ET AL: "Humanisation of monoclonal antibodies for therapy", 《SEMIN IMMUNOL》, vol. 2, no. 6, 30 November 1990 (1990-11-30), pages 457 - 466 *

Also Published As

Publication number Publication date
KR20120093229A (ko) 2012-08-22
JP2013505938A (ja) 2013-02-21
US20120094395A1 (en) 2012-04-19
EP2480252A4 (en) 2014-04-30
AU2010298264B2 (en) 2014-10-23
US20120094301A1 (en) 2012-04-19
CA2775291A1 (en) 2011-03-31
US20110071054A1 (en) 2011-03-24
WO2011038069A1 (en) 2011-03-31
US20110070230A1 (en) 2011-03-24
EP2480252A1 (en) 2012-08-01
US20110071276A1 (en) 2011-03-24
AU2010298264A1 (en) 2012-04-19
US20110070229A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
CN102573895A (zh) 减少抗-抗体反应的方法、组合物和试剂盒
CN113330036B (zh) 结合pd-l1和ox40的双特异性抗体
KR20190101989A (ko) 항 gpc3 항체
CN114702578B (zh) 新型冠状病毒Omicron突变株特异性抗体及其应用
CN116836270B (zh) 一种抗蓝舌病毒vp7蛋白的单克隆抗体及制备方法与用途
CN116589564B (zh) 抗aav5抗体及快速aav5滴度测定elisa试剂盒
CN111153992A (zh) 结核分枝杆菌lam的单克隆抗体及其用途
Barrett et al. Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype
CN114409791A (zh) 一种全人源抗人红细胞RhD全分子IgG及其制备方法和应用
CN117088976B (zh) 一种抗nfl的单克隆抗体
US20220127375A1 (en) Producing compositions comprising two or more antibodies
CN114349855B (zh) 新型冠状病毒Delta突变株特异性抗体及其应用
CN112521493B (zh) 抗口蹄疫o型病毒单克隆抗体及其应用
CN118994396A (zh) 一种抗cd31的单克隆纳米抗体及其应用
Williams et al. Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR
CN119431580B (zh) 一种抗人tigit单克隆抗体及其应用
CN120623352B (zh) 抗human IgG的抗体、其制备方法及用途
CN120025426B (zh) 一种针对痘病毒膜相关蛋白l1r的人源化抗体及其应用
CN119841951B (zh) 一种抗bcma抗体或其抗原结合片段及其制备方法和应用
CN120665199B (zh) 抗human IgG的抗体、其制备方法及用途
CN120829514A (zh) 一种抗血型抗原的抗体及其应用
CN118146360A (zh) 针对SARS-CoV-2 S蛋白的抗体1A01及其用途
KR20250122027A (ko) 고양이 혈청 아밀로이드 a 단백질에 대한 단일클론항체, 이를 생산하는 융합 세포주 및 이의 용도
CN120775055A (zh) 一种抗泛种特异性抗原疟原虫乳酸脱氢酶的抗体及其应用
KR20250122026A (ko) 고양이 혈청 아밀로이드 a 단백질에 대한 단일클론항체, 이를 생산하는 융합 세포주 및 이의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120711